MU Research Reactor to supply radioisotope for targeted cancer therapy

MURR® has entered into an exclusive agreement to provide no-carrier-added lutetium-177 to Advanced Accelerator Applications, SA (AAA), a Novartis company.

Jan. 25, 2021
Contact: Austin Fitzgerald, 573-882-6217,

The University of Missouri Research Reactor (MURR®) has entered into an exclusive multi-year agreement with Advanced Accelerator Applications International, SA (AAA), a Novartis company, to provide a key ingredient in a targeted therapy for certain types of cancerous tumors. The agreement covers medical markets in the U.S. and around the world… (Read more).